Med24
peptide-development 1. 12. 2026 • 2 min read • Clinical obesity

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A retrospective study examined 12-month weight loss results comparing sleeve gastrectomy (SG) and tirzepatide in a diverse, urban patient population. The study evaluated changes in BMI, excess weight loss, and total weight loss (TWL) percentage at 3, 6, and 12 months, adhering to ASMBS reporting standards. Linear mixed models demonstrated statistically significant differences in weight loss between the SG and tirzepatide cohorts across all measured time points. The SG cohort experienced a greater BMI reduction, achieving 12% TWL and 7 kg/m2 weight loss at 12 months, compared to the tirzepatide cohort which showed a 2% BMI reduction. This indicates a more substantial weight loss effect with SG compared to tirzepatide within this specific patient group. The study highlights the continued effectiveness of metabolic and bariatric surgery as a method for achieving significant weight loss. The research was conducted within a single center. The findings contribute to the understanding of comparative outcomes between surgical and pharmacological interventions for severe obesity. The study’s focus on a diverse patient population is intended to improve the generalizability of the results. Individualized treatment decisions remain important, considering patient preference, cost, and specific metabolic goals. The research emphasizes the importance of ongoing investigation into obesity treatment options.

Sponsored content

Original Scientific Source
Clinical obesity
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity
peptide-development

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity

Aims Glucagon-like peptide-1 (GLP-1) receptor agonist-based medicines are highly effective treatments for overweight and obesity, but population-scale real-world evidence remains limited, particularly in self-funded settings where treatment choice may be influenced by relative price. We aimed to characterise provider...

14. 10. 2026 Read article →
Advertisement